Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter StudyCollin M. Blakely, David M. Jablons, D. Lucas Kerr et al.|Journal of Clinical Oncology|2024Cited by 65
Phase II trial of neoadjuvant osimertinib for surgically resectable <i>EGFR</i>-mutated non-small cell lung cancer.Jacqueline V. Aredo, Collin M. Blakely, Anatoly Urisman et al.|Journal of Clinical Oncology|2023Cited by 23
P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung CancerJulia Rotow, C. Blakely, Anatoly Urisman et al.|Journal of Thoracic Oncology|2019Cited by 8
P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated ResultsC. Blakely, David M. Jablons, Anatoly Urisman et al.|Journal of Thoracic Oncology|2021Cited by 7